This site uses cookies in order to improve your user experience and to provide content tailored specifically to your interests. Detailed information on the use of cookies on this website is provided in our Privacy Policy. You can also manage your preferences there. By using this website, you consent to the use of cookies.
Stepping up the pace in vaccine development and production
GSK is collaborating with Siemens and ATOS to optimize vaccine development and production
Stepping up the pace in vaccine development and production
GSK is collaborating with Siemens and ATOS to optimize vaccine development and production
Pharmaceuticals
GlaxoSmithKline (GSK)
Greenford, Middlesex United Kingdom
Developing vaccines is usually a costly and time-consuming process. It
can take up to several years.
Right now, vaccine development typically progresses in many small
silos, each digitalized to some extent in its own environment, but with few
connections between them. Often one group depends on the completion of the
work by another team to be able to access data. This is where there is
potential for optimization.
Digital Enterprise
solution from Siemens :
SIPAT process analysis
technology
Totally Integrated
Automation Portal (TIA Portal)
AI and ATOS software
structure
Significant
improvement of the entire value chain through integration and
digitalization
Easier
and earlier access to results
Faster and more comprehensive feedback
Better
ability to predict and share outcomes
Providing
better oversight of the entire process
Faster
vaccine development with best information available during production
using the digital twin
Advantages
of the Digital Twin:
Testing
stages in the process
Gaining
insights in a virtual environment right at the outset
Predicting
the performance of the process
Anticipating
deviation and steering
the control back to the optimal production
Ensuring
reliable supply through feeding back the data obtained from real runs
with machine learning
Using obtained data to optimize the digital twin, the
products and processes from an early stage
Every day, GSK manufactures around two million vaccine doses, making it
one of the world’s largest suppliers. Now GSK is turning to digitalization to
help speed things up: collaborating with Siemens, it aims to create and
introduce digital twins of the entire vaccine manufacturing process for all new
vaccines. In other words, the digital twins of the product, production, and
performance will be linked together.